WHAT IS CLAIMED IS:

1. A stable formulation comprising at least one monoclonal antibody that specifically binds to PCSK9, wherein PCSK9 comprises the amino acids of SEQ ID NO 1, the monoclonal antibody in an amount of 40 mg/ml to 300 mg/ml, and a pharmaceutically acceptable buffer in an amount of 0.05 mM to 40 mM, and a pharmaceutically acceptable surfactant in an amount that is 0.004% w/v to 20% w/v, and at least one pharmaceutically acceptable stabilizer of 0.5% w/v to 10% w/v, wherein the stable formulation has a pH of between 4.0 to 6.0.

2. The stable formulation of claim1, wherein the monoclonal antibody comprises:
    a) a light chain variable region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO: 23 and a heavy chain variable region that comprises and amino acid sequence that is at least 90% identical to that of SEQ ID NO:49,
    b) a light chain variable region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO: 12 and a heavy chain variable region that comprises and amino acid sequence that is at least 90% identical to that of SEQ ID NO:67,
    c) a light chain variable region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO:465 and a heavy chain variable region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO:463,
    d) a light chain variable region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO: 461 and a heavy chain variable region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO:459,
    e) a light chain variable region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO: 485 and a heavy chain variable region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO:483;
    f) a light chain variable region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO:582 and a heavy chain variable

region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO:583;

g) a light chain complementarity determining region (CDR) of the CDRL1 sequence in SEQ ID NO:23, a CDRL2 of the CDRL2 sequence in SEQ ID NO:23, and a CDRL3 of the CDRL3 sequence in SEQ ID NO:23, and a heavy chain complementarity determining region (CDR) of the CDRH1 sequence in SEQ ID NO: 49, a CDRH2 of the CDRH2 sequence in SEQ ID NO:49, and a CDRH3 of the CDRH3 sequence in SEQ ID NO:49;

h) a light chain complementarity determining region (CDR) of the CDRL1 sequence in SEQ ID NO:465, a CDRL2 of the CDRL2 sequence in SEQ ID NO:465, and a CDRL3 of the CDRL3 sequence in SEQ ID NO:465, and a heavy chain complementarity determining region (CDR) of the CDRH1 sequence in SEQ ID NO: 463, a CDRH2 of the CDRH2 sequence in SEQ ID NO: 463, and a CDRH3 of the CDRH3 sequence in SEQ ID NO:463;

i) a light chain complementarity determining region (CDR) of the CDRL1 sequence in SEQ ID NO:12, a CDRL2 of the CDRL2 sequence in SEQ ID NO:12, and a CDRL3 of the CDRL3 sequence in SEQ ID NO:12, and a heavy chain complementarity determining region (CDR) of the CDRH1 sequence in SEQ ID NO: 67, a CDRH2 of the CDRH2 sequence in SEQ ID NO: 67, and a CDRH3 of the CDRH3 sequence in SEQ ID NO:67;

j) a light chain complementarity determining region (CDR) of the CDRL1 sequence in SEQ ID NO:461, a CDRL2 of the CDRL2 sequence in SEQ ID NO:461, and a CDRL3 of the CDRL3 sequence in SEQ ID NO:461, and a heavy chain complementarity determining region (CDR) of the CDRH1 sequence in SEQ ID NO: 459, a CDRH2 of the CDRH2 sequence in SEQ ID NO: 459, and a CDRH3 of the CDRH3 sequence in SEQ ID NO:459; or

k) a light chain complementarity determining region (CDR) of the CDRL1 sequence in SEQ ID NO:485, a CDRL2 of the CDRL2 sequence in SEQ ID NO:485, and a CDRL3 of the CDRL3 sequence in SEQ ID NO:485, and a heavy chain complementarity determining region (CDR) of the CDRH1 sequence in SEQ ID NO: 483, a CDRH2 of the CDRH2 sequence in SEQ ID NO: 483, and a CDRH3 of the CDRH3 sequence in SEQ ID NO:483; or

l) a light chain complementarity determining region (CDR) of the CDRL1 sequence in SEQ ID NO:582, a CDRL2 of the CDRL2 sequence in SEQ ID

NO:582, and a CDRL3 of the CDRL3 sequence in SEQ ID NO:582, and a heavy chain complementarity determining region (CDR) of the CDRH1 sequence in SEQ ID NO: 583, a CDRH2 of the CDRH2 sequence in SEQ ID NO: 583, and a CDRH3 of the CDRH3 sequence in SEQ ID NO:583.

3. The stable formulation of claim 2, wherein the monoclonal antibody comprises: a light chain complementarity determining region of the CDRL1 sequence in SEQ ID NO:23, a CDRL2 of the CDRL2 sequence in SEQ ID NO:23, and a CDRL3 of the CDRL3 sequence in SEQ ID NO:23, and a heavy chain complementarity determining region (CDR) of the CDRH1 sequence in SEQ ID NO: 49, a CDRH2 of the CDRH2 sequence in SEQ ID NO: 49, and a CDRH3 of the CDRH3 sequence in SEQ ID NO: 49.

4. The stable formulation of claim 3, wherein the heavy chain comprises: a CDR1 comprising SEQ ID NO: 308, a CDR2 comprising SEQ ID NO: 175, and a CDR3 comprising SEQ ID NO: 180.

5. The stable formulation of claim 3, wherein the heavy chain comprises: a CDR1 comprising SEQ ID NO: 368, a CDR2 comprising SEQ ID NO: 175, and a CDR3 comprising SEQ ID NO: 180.

6. The stable formulation of claim 3, wherein the light chain comprises: a CDR1 comprising SEQ ID NO: 158, a CDR2 comprising SEQ ID NO: 162, and a CDR3 comprising SEQ ID NO: 395.

7. The stable formulation of claim 6, wherein the heavy chain comprises: a CDR1 comprising SEQ ID NO: 308, a CDR2 comprising SEQ ID NO: 175, and a CDR3 comprising SEQ ID NO: 180.

8. The stable formulation of claim 6, wherein the heavy chain comprises: a CDR1 comprising SEQ ID NO: 368, a CDR2 comprising SEQ ID NO: 175, and a CDR3 comprising SEQ ID NO: 180.

9. The stable formulation of claim 2, wherein each CDR is defined in accordance with the Kabat definition, the Chothia definition, the combination of the Kabat definition and the Chothia definition, the AbM definition, or the contact definition of CDR.

10. The stable formulation of claim 9, wherein each CDR is defined in accordance with the CDR definition of Kabat.

11. The stable formulation of claim 9, wherein each CDR is defined in accordance with the CDR definition of Chothia.

12. The stable formulation of claim 2 wherein the monoclonal antibody comprises:

a) a light chain variable region that comprises the amino acid sequence SEQ ID NO: 23 and a heavy chain variable region comprises the amino acid sequence of SEQ ID NO:49,

b) a light chain variable region that comprises the amino acid sequence of SEQ ID NO:465 and a heavy chain variable region that comprises the amino acid of SEQ ID NO:463,

c) a light chain variable region that comprises the amino acid sequence of SEQ ID NO: 12 and a heavy chain variable region that comprises the amino acid sequence of SEQ ID NO:67,

d) a light chain variable region that comprises the amino acid sequence of SEQ ID NO: 461 and a heavy chain variable region that comprises the amino acid sequence of SEQ ID NO:459,

e) a light chain variable region that comprises the amino acid sequence of SEQ ID NO: 485 and a heavy chain variable region that comprises the amino acid sequence of SEQ ID NO:483, or

f) a light chain variable region that comprises an amino acid sequence of SEQ ID NO:582 and a heavy chain variable region that comprises an amino acid sequence of SEQ ID NO:583.

13. The stable formulation of claim 2, wherein the monoclonal antibody further comprises:

a. the light chain constant sequence of SEQ ID NO: 156;

b. the light chain constant sequence of SEQ ID NO: 157;

c. the heavy chain constant sequence of SEQ ID NO: 154;

d. the heavy chain constant sequence of SEQ ID NO: 155;

e. the light chain constant sequence of SEQ ID NO: 156 and the heavy chain constant sequence of SEQ ID NO: 154,

f. the light chain constant sequence of SEQ ID NO: 157 and the heavy chain constant sequence of SEQ ID NO: 154;

g. the light chain constant sequence of SEQ ID NO: 156 and the heavy chain constant sequence of SEQ ID NO: 155; or

h. the light chain constant sequence of SEQ ID NO: 157 and the heavy chain constant sequence of SEQ ID NO: 155.

14. The stable formulation of claim 2, wherein the pharmaceutically acceptable buffer is selected from the group consisting of glutamate, phosphate, phosphate buffered saline, sodium acetate, sodium citrate, and Tris buffer.

15. The stable formulation of claim 14, wherein said pharmaceutically acceptable buffer is sodium acetate.

16. The stable formulation of claim 15, wherein the pharmaceutically acceptable buffer is present in an amount of 10-20 mM.

17. The stable formulation of claim 2, wherein said pharmaceutically acceptable surfactant is polysorbate 80 or polysorbate 20.

18. The stable formulation of claim 16, wherein said pharmaceutically acceptable surfactant is polysorbate 80.

19. The stable formulation of claim 16, wherein said pharmaceutically acceptable surfactant is polysorbate 20.

20. The stable formulation of any of claims 17, 18 or 19 wherein pharmaceutically acceptable surfactant is present in an amount of 0.004% w/v to 0.01% w/v.

21. The stable formulation of claim 2, wherein said pharmaceutically acceptable stabilizer is selected from the group consisting of a polyhydroxy hydrocarbon, a disaccharide, a polyol, proline, arginine, lysine, methionine, taurine, and benzyl alcohol.

22. The stable formulation of claim 21, wherein said stabilizer is a polyhydroxy hydrocarbon selected from the group consisting of sorbital, mannitol, and glycerol.

23. The stable formulation of claim 20, wherein said stabilizer is sorbitol.

24. The stable formulation of claim 21, wherein said stabilizer is a disaccharide selected from the group consisting of sucrose, maltose, lactose, fructose and trehelose.

25. The stable formulation of claim 20, wherein said stabilizer is sucrose.

26. The stable formulation of claim 25, wherein the stabilizer is present in an amount of 9% w/v.

27. The stable formulation of claim 20, wherein the stabilizer is proline.

28. The stable formulation of claim 27, wherein the proline is present in an amount of between 2% and 3% w/v.

29. The stable formulation of claim 26, wherein the formulation has a pH of between 5.0 to 5.5.

30. The stable formulation of claim 28, wherein the formulation has a pH of between 5.0 to 5.5.

31. The stable formulation of claim 26 wherein the stable formulation comprises a viscosity of 30 cP or less at 25°C.

32. The stable formulation of claim 28, wherein the stable formulation comprises a viscosity of 30 cP or less at 25°C.

33. The stable formulation of claim 28, wherein the amount of monoclonal antibody is 70 mg/ml to 150 mg/ml and the stable formulation comprises a viscosity of 12 cP or less at 25°C.

34. The stable formulation of claim 29 comprising between 250 mOsmol/kg to 350 mOsmol/kg.

35. The stable formulation of claim 30, comprising between 250 mOsmol/kg to 350 mOsmol/kg.

36. The stable formulation of claim 29, wherein the stable formulation remains stable for at least 3, 6, 12 or 24 months.

37. The stable formulation of claim 30, wherein the stable formulation remains stable for at least 3, 6, 12 or 24 months.

38. The stable formulation of claim 36, wherein the monoclonal antibody comprises a light chain variable region that is at least 90% identical to that of amino acid sequence of SEQ ID NO: 23 and a heavy chain variable region that is at least 90% identical to that of amino acid sequence of SEQ ID NO: 49.

39. The stable formulation of claim 36, wherein the monoclonal antibody comprises a light chain complementarity determining region (CDR) of the CDRL1 sequence in SEQ ID NO:23, a CDRL2 of the CDRL2 sequence in SEQ ID NO:23, and a CDRL3 of the CDRL3 sequence in SEQ ID NO:23, and a heavy chain complementarity determining region (CDR) of the CDRH1 sequence in SEQ ID NO: 49, a CDRH2 of the CDRH2 sequence in SEQ ID NO:49, and a CDRH3 of the CDRH3 sequence in SEQ ID NO:49.

40. The stable formulation of claim 36, wherein the monoclonal antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:23 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:49.

41. The stable formulation of claim 36, wherein the heavy chain comprises: a CDR1 comprising SEQ ID NO: 308, a CDR2 comprising SEQ ID NO: 175, and a CDR3 comprising SEQ ID NO: 180, and the light chain comprises: a CDR1 comprising SEQ ID NO: 158, a CDR2 comprising SEQ ID NO: 162, and a CDR3 comprising SEQ ID NO: 395.

42. The stable formulation of claim 36, wherein the heavy chain comprises: a CDR1 comprising SEQ ID NO: 368, a CDR2 comprising SEQ ID NO: 175, and a CDR3 comprising SEQ ID NO: 180, and the light chain comprises: a CDR1 comprising SEQ ID NO: 158, a CDR2 comprising SEQ ID NO: 162, and a CDR3 comprising SEQ ID NO: 395.

43. The stable formulation of claim 37, wherein the monoclonal antibody comprises a light chain variable region that is at least 90% identical to that of amino acid sequence of SEQ ID NO:23 and a heavy chain variable region that is at least 90% identical to that of amino acid sequence of SEQ ID NO:49.

44. The stable formulation of claim 37, wherein the monoclonal antibody comprises a light chain complementarity determining region (CDR) of the CDRL1 sequence in SEQ ID NO:23, a CDRL2 of the CDRL2 sequence in SEQ ID NO:23, and a CDRL3 of the CDRL3 sequence in SEQ ID NO:23, and a heavy chain complementarity determining region (CDR) of the CDRH1 sequence in SEQ ID NO: 49, a CDRH2 of the CDRH2 sequence in SEQ ID NO:49, and a CDRH3 of the CDRH3 sequence in SEQ ID NO:49.

45. The stable formulation of claim 37, wherein the monoclonal antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:23 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:49.

46. The stable formulation of claim 37, wherein the heavy chain comprises: a CDR1 comprising SEQ ID NO: 308, a CDR2 comprising SEQ ID NO: 175, and a CDR3 comprising SEQ ID NO: 180, and the light chain comprises: a CDR1 comprising

SEQ ID NO: 158, a CDR2 comprising SEQ ID NO: 162, and a CDR3 comprising SEQ ID NO: 395.

47. The stable formulation of claim 37, wherein the heavy chain comprises: a CDR1 comprising SEQ ID NO: 368, a CDR2 comprising SEQ ID NO: 175, and a CDR3 comprising SEQ ID NO: 180, and the light chain comprises: a CDR1 comprising SEQ ID NO: 158, a CDR2 comprising SEQ ID NO: 162, and a CDR3 comprising SEQ ID NO: 395.

48. The stable formulation of claim 36, wherein the monoclonal antibody comprises a light chain variable region that is at least 90% identical to that of SEQ ID NO:465 and a heavy chain variable region that is at least 90% identical to that of SEQ ID NO:463.

49. The stable formulation of claim 37, wherein the monoclonal antibody comprises a light chain variable region that is at least 90% identical to that of SEQ ID NO:465 and a heavy chain variable region that is at least 90% identical to that of SEQ ID NO:463.

50. The stable formulation of claim 36, wherein the monoclonal antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 465 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 463 and where rein the amount of the monoclonal antibody is 150 mg/ml.

51. A stable formulation, comprising
    a. a monoclonal antibody in an amount of 70 mg/ml to 200 mg/ml, said monoclonal antibody comprising:
        i) a light chain variable region that comprises the amino acid sequence having at least 90% identity to the sequence of SEQ ID NO: 23 and a heavy chain variable region that comprises the amino acid sequence having at least 90% identity to the sequence of SEQ ID NO: 49;
        ii) a light chain complementarity determining region (CDR) of the CDRL1 sequence in SEQ ID NO:23, a CDRL2 of the

CDRL2 sequence in SEQ ID NO:23, and a CDRL3 of the CDRL3 sequence in SEQ ID NO:23, and a heavy chain complementarity determining region (CDR) of the CDRH1 sequence in SEQ ID NO: 49, a CDRH2 of the CDRH2 sequence in SEQ ID NO:49, and a CDRH3 of the CDRH3 sequence in SEQ ID NO:49; or

iii) a light chain variable region that comprises the amino acid sequence of SEQ ID NO:23 and a heavy chain variable region that comprises the amino acid sequence of SEQ ID NO:49;

(b) 10 mM sodium acetate;

(c) 9.0% w/v sucrose;

(d) 0.004% to 0.01% w/v polysorbate 20 or polysorbate 80, and

(e) a pH of 5.2.

52. A stable formulation comprising: a monoclonal antibody in an amount of 70 mg/ml to 200 mg/ml, said monoclonal antibody comprising:

i) a light chain variable region that comprises the amino acid sequence having at least 90% identity to the sequence of SEQ ID NO:23 and a heavy chain variable region that comprises the amino acid sequence having at least 90% identity to the sequence of SEQ ID NO:49;

ii) a light chain complementarity determining region (CDR) of the CDRL1 sequence in SEQ ID NO:23, a CDRL2 of the CDRL2 sequence in SEQ ID NO:23, and a CDRL3 of the CDRL3 sequence in SEQ ID NO:23, and a heavy chain complementarity determining region (CDR) of the CDRH1 sequence in SEQ ID NO: 49, a CDRH2 of the CDRH2 sequence in SEQ ID NO:49, and a CDRH3 of the CDRH3 sequence in SEQ ID NO:49; or

iii) a light chain variable region that comprises the amino acid sequence of SEQ ID NO:23 and a heavy chain variable region that comprises the amino acid sequence of SEQ ID NO:49;

(b) 10 mM sodium acetate;

(c) between 2.0% to 3.0% w/v proline;

(d) 0.01% w/v polysorbate 20 or polysorbate 80, and

(e) a pH of 5.0.

WHAT IS CLAIMED IS:

1. A stable formulation comprising at least one monoclonal antibody that specifically binds to PCSK9, wherein PCSK9 comprises the amino acids of SEQ ID NO 1, the monoclonal antibody in an amount of about 40 mg/ml to about 300 mg/ml, and a pharmaceutically acceptable buffer in an amount of about .05 mM to about 40 mM, and a pharmaceutically acceptable surfactant in an amount that is about .01% w/v to about 20% w/v, and at least one pharmaceutically acceptable stabilizer of about 0.5% w/v to about 10% w/v, wherein the stable formulation has a pH of between about 4.0 to about 6.0.
2. The stable formulation of any of claim1, wherein the monoclonal antibody comprises:
    a) a light chain variable region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO: 23 and a heavy chain variable region that comprises and amino acid sequence that is at least 90% identical to that of SEQ ID NO:49,
    b) a light chain variable region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO:465 and a heavy chain variable region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO:463,
    c) ,a light chain variable region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO: 461 and a heavy chain variable region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO:459,

d) a light chain variable region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO: 485 and a heavy chain variable region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO:483; or

e) a light chain variable region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO:582 and a heavy chain variable region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO:583.

3. The stable formulation of claim 2 wherein the monoclonal antibody comprises:

a) a light chain variable region that comprises the amino acid sequence SEQ ID NO: 23 and a heavy chain variable region comprises the amino acid sequence of SEQ ID NO:49,

b) a light chain variable region that comprises the amino acid sequence of SEQ ID NO:465 and a heavy chain variable region that comprises the amino acid of SEQ ID NO:463,

c) a light chain variable region that comprises the amino acid sequence of SEQ ID NO: 12 and a heavy chain variable region that comprises the amino acid sequence of SEQ ID NO:67,

d) a light chain variable region that comprises the amino acid sequence of SEQ ID NO: 461 and a heavy chain variable region that comprises the amino acid sequence of SEQ ID NO:459,

e) a light chain variable region that comprises the amino acid sequence of SEQ ID NO: 485 and a heavy chain variable region that comprises the amino acid sequence of SEQ ID NO:483, or

f) a light chain variable region that comprises an amino acid sequence of SEQ ID NO:582 and a heavy chain variable region that comprises an amino acid sequence of SEQ ID NO:583.

4. The stable formulation of claim 2 wherein the monoclonal antibody is selected from the group consisting of 21B12, 11F1, 31H4, 8A3, and 8A1.

5. The stable formulation of claim 2, wherein the pharmaceutically acceptable buffer is selected from the group consisting of glutamate, phosphate, phosphate buffered saline, sodium acetate, sodium citrate, and Tris buffer.

6. The stable formulation of claim 5, wherein said pharmaceutically acceptable buffer is sodium acetate.

7. The stable formulation of claim 6, wherein the pharmaceutically acceptable buffer is present in an amount of 10-20 mM.

8. The stable formulation of claim 2, wherein said pharmaceutically acceptable surfactant is polysorbate 80 or polysorbate 20.

9. The stable formulation of claim 7, wherein said pharmaceutically acceptable surfactant is polysorbate 80.

10. The stable formulation of claim 7, wherein said pharmaceutically acceptable surfactant is polysorbate 20.

11. The stable formulation of any of claims 8, 9 or 10 wherein pharmaceutically acceptable surfactant is present in an amount of about 0.004% w/v to about 0.01% w/v.

12. The stable formulation of any of claim 2, wherein said pharmaceutically acceptable stabilizer is selected from the group consisting of a polyhydroxy hydrocarbon, a disaccharide, a polyol, proline, arginine, lysine, methionine, taurine, and benzyl alcohol.

13. The stable formulation of claim 12, wherein said stabilizer is a polyhydroxy hydrocarbon selected from the group consisting of sorbital, mannitol, and glycerol.

14. The stable formulation of claim 11, wherein said stabilizer is sorbitol.

15. The stable formulation of claim 12, wherein said stabilizer is a disaccharide selected from the group consisting of sucrose, maltose, lactose, fructose and trehelose.

16. The stable formulation of claim 11, wherein said stabilizer is sucrose.

17. The stable formulation of claim 16, wherein the stabilizer is present in an amount of about 9% w/v.

18. The stable formulation of claim 11, wherein the stabilizer is proline.

19. The stable formulation of claim 18, wherein the proline is present in an amount of between about 2% and 3% w/v.

20. The stable formulation of claim 17, wherein the formulation has a pH of between about 5.0 to about 5.5.

21. The stable formulation of claim 19, wherein the formulation has a pH of between about 5.0 to about 5.5.

22. The stable formulation of claim 17, wherein the stable formulation comprises a viscosity of 30 cP or less at 25°C.

23. The stable formulation of claim 19, wherein the stable formulation comprises a viscosity of 30 cP or less at 25°C.

24. The stable formulation of claim 19, wherein the amount of monoclonal antibody is about 70 mg/ml to about 150 mg/ml and the stable formulation comprises a viscosity of 12 cP or less at 25°C.

25. The stable formulation of claim 20 comprising between about 250 mOsmol/kg to about 350 mOsmol/kg.

26. The stable formulation of claim 21, comprising between about 250 mOsmol/kg to about 350 mOsmol/kg.

27. The stable formulation of claim 20, wherein the stable formulation remains stable for at least 3, 6, 12 or 24 months.

28. The stable formulation of claim 21, wherein the stable formulation remains stable for at least 3, 6, 12 or 24 months.

29. The stable formulation of claim 27, wherein the monoclonal antibody comprises a light chain variable region that is at least 90% identical to that of amino acid sequence of SEQ ID NO:23 and a heavy chain variable region that is at least 90% identical to that of amino acid sequence of SEQ ID NO:49.

30. The stable formulation of claim 27, wherein the monoclonal antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:23 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:49, and wherein the amount of the monoclonal antibody is about 70 mg/ml.

31. The stable formulation of claim 28, wherein the monoclonal antibody comprises a light chain variable region that is at least 90% identical to that of amino acid sequence of SEQ ID NO:23 and a heavy chain variable region that is at least 90% identical to that of amino acid sequence of SEQ ID NO:49.

32. The stable formulation of claim 28, wherein the monoclonal antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:23 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:49, and wherein the amount of the monoclonal antibody is about 140 mg/ml.

33. The stable formulation of claim 27, wherein the monoclonal antibody comprises a light chain variable region that is at least 90% identical to that of SEQ ID NO:465

and a heavy chain variable region that is at least 90% identical to that of SEQ ID NO:463.

34. The stable formulation of claim 28, wherein the monoclonal antibody comprises a light chain variable region that is at least 90% identical to that of SEQ ID NO:463 and a heavy chain variable region that is at least 90% identical to that of SEQ ID NO:463.

35. The stable formulation of any of claim 27, wherein the monoclonal antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:465 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:463 and where rein the amount of the monoclonal antibody is about 150 mg/ml.

36. The stable formulation of any of claim 27, wherein the monoclonal antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:465 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:463 and where rein the amount of the monoclonal antibody is about 150 mg/ml.

37. A stable formulation, comprising

a. a monoclonal antibody in an amount of about 70 mg/ml to about 200 mg/ml, said monoclonal antibody comprising:

i) a light chain variable region that comprises the amino acid sequence having at least 90% identity to the sequence of SEQ ID NO: 577 and a heavy chain variable region that comprises the amino acid sequence having at least 90% identity to the sequence of SEQ ID NO: 576;

ii) a light chain variable region that comprises the amino acid sequence of SEQ ID NO: 577 and a heavy chain variable region that comprises the amino acid sequence of SEQ ID NO:576;

iii) a light chain variable region that comprises the amino acid sequence having at least 90% identity to the sequence of SEQ ID NO: 588 and a heavy chain variable region that comprises the amino acid sequence having at least 90% identity to the sequence of SEQ ID NO: 599; or

iv) a light chain variable region that comprises the amino acid sequence of SEQ ID NO: 588 and a heavy chain variable region that comprises the amino acid sequence of SEQ ID NO:589;

(b) about 10 mM sodium acetate;

(c) about 9.0% w/v sucrose;

(d) about 0.004% to about 0.01% w/v polysorbate 20 or polysorbate 80, and

(e) a pH of about 5.2.

38. A stable formulation comprising: a monoclonal antibody in an amount of about 70 mg/ml to about 200 mg/ml, said monoclonal antibody comprising:

i) a light chain variable region that comprises the amino acid sequence having at least 90% identity to the sequence of SEQ ID NO: 577 and a heavy chain variable region that comprises the amino acid sequence having at least 90% identity to the sequence of SEQ ID NO: 576;

ii) a light chain variable region that comprises the amino acid sequence of SEQ ID NO: 577 and a heavy chain variable region that comprises the amino acid sequence of SEQ ID NO:576;

iii) a light chain variable region that comprises the amino acid sequence having at least 90% identity to the sequence of SEQ ID NO: 588 and a heavy chain variable region that comprises the amino acid sequence having at least 90% identity to the sequence of SEQ ID NO: 589; or

iv) a light chain variable region that comprises the amino acid sequence of SEQ ID NO: 588 and a heavy chain variable region that comprises the amino acid sequence of SEQ ID NO:589;

(b) about 10 mM sodium acetate;

(c) between about 2.0% to 3.0% w/v proline;

(d) about 0.01% w/v polysorbate 20 or polysorbate 80, and

(e) a pH of about 5.0.

39. Use of at least one anti-PCSK9 antibody in the manufacture of a medicament for lowering serum LDL cholesterol in a patient wherein the anti-PCSK9 antibody is to be administered to the patient in need thereof at a dose of about 10 mg to about 3000 mg, thereby lowering said serum LDL cholesterol level by at least about 15%.

40. Use of at least one anti-PCSK9 antibody in the manufacture of a medicament for treating or preventing a cholesterol related disorder in a patient having a serum LDL cholesterol level where the anti-PCSK9 antibody is to be administered to the patient in need thereof at a dose of about 10 mg to about 3000 mg, thereby treating or preventing the cholesterol related disorder in said patient.

41. The use of claim 40, wherein the cholesterol related disorder is selected from the group consisting of familial hypercholesterolemia including heterozygous familial hypercholesterolemia and homozygous familial hypercholesterolemia, non-familial hypercholesterolemia, elevated lipoprotein (a), heart disease, metabolic syndrome, diabetes, coronary heart disease, stroke, cardiovascular disease, Alzheimer's disease, peripheral arterial disease, hyperlipidemia and dyslipidemia.

42. The use of claim 39, wherein the serum LDL cholesterol level of said patient is lowered by an amount selected from the group consisting of a) at least about 15%, b) at least about 30%, c) at least about 40%, d) at least about 50%, and e) at least about 60%.

43. The use of claim 42, wherein the anti-PCSK9 antibody comprises,

(a) a light chain variable region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO: 23 and a heavy chain variable region that comprises and amino acid sequence that is at least 90% identical to that of SEQ ID NO:49;

(b) a light chain variable region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO: 12 and a heavy chain variable region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO:67;

(c) a light chain variable region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO: 461 and a heavy chain variable region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO:459;

(d) a light chain variable region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO:465 and a heavy chain variable

region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO:463;

(e) a light chain variable region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO: 485 and a heavy chain variable region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO:483; or

(f) a light chain variable region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO:582 and a heavy chain variable region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO:583.

44. The use of claim 42, wherein the anti-PCSK9 antibody comprises,

(a) a light chain variable region that comprises an amino acid sequence, SEQ ID NO: 23, and a heavy chain variable region that comprises and amino acid sequence, SEQ ID NO:49;

(b) a light chain variable region that comprises an amino acid sequence, SEQ ID NO: 12, and a heavy chain variable region that comprises an amino acid sequence, SEQ ID NO:67;

(c) a light chain variable region that comprises amino acid sequence SEQ ID NO: 461 and a heavy chain variable region that comprises amino acid sequence SEQ ID NO:459;

(d) a light chain variable region that comprises the amino acid sequence of SEQ ID NO:465 and a heavy chain variable region that comprises the amino acid sequence of SEQ ID NO:463; or

(e) a light chain variable region that comprises the amino acid sequence of SEQ ID NO: 485 and a heavy chain variable region that comprises the amino acid sequence of SEQ ID NO:483; or

(f) a light chain variable region that comprises the amino acid sequence of SEQ ID NO: 582 and a heavy chain variable region that comprises the amino acid sequence of SEQ ID NO:583.

45. The use of claim 42, wherein the at least one anti-PCSK9 antibody is selected from the group consisting of 21B12, 11F1,31H4, 8A3, and 8A1.

46. The use of claim 43, wherein the anti-PCSK9 antibody is to be administered to a patient at a dose selected from the group consisting of: a) about 45 mg to about 450 mg, b) about 140 mg to about 200 mg, c) about 140 mg to about 180 mg, d) about 140 mg to about 170 mg, e) about 140 mg, f) about 150 mg, g) about 420 mg, h) about 450 mg, i) about 600 mg, j) about 700 mg, k) about 1400 mg, l) about 1200 mg, m) about 420 mg to about 3000 mg, n) about 1000 mg to about 3000 mg, o) about 3000 mg.

47. The use of claim 46, wherein the anti-PCSK9 antibody is to be administered to a patient on a schedule selected from the group consisting of: (1) once a week, (2) once every two weeks, (3) once a month, (4) once every other month, (5) once every three months (6)once every six months and (7) once every twelve months.

48. The use of 46, wherein the at least one anti-PCSK9 antibody is to be administered parenterally.

49. The use of claim 48, wherein the at least one anti-PCSK9 antibody is to be administered intravenously.

50. The use of claim 48, wherein the at least one anti-PCSK9 antibody is to be administered subcutaneously.

51. The use of claim 50, wherein the at least one anti-PCSK9 antibody comprises a light chain variable region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO: 23 and a heavy chain variable region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO:49.

52. The use of claim 50, wherein the at least one anti-PCSK9 antibody comprises a light chain variable region that comprises the amino acid sequence of SEQ ID NO: 23 and a heavy chain variable region that comprises the amino acid sequence of SEQ ID NO:49.

53. The use of claim 50, wherein the at least one anti-PCSK9 antibody is 21B12.

54. The use of claim 52, wherein the anti-PCSK9 antibody is to be administered to a patient at a dose of about 35 mg to about 70 mg subcutaneously once a week, and wherein the serum LDL cholesterol level of the patient is lowered at least about 30 -50% for about 7-10 days.

55. The use of claim 52, wherein the anti-PCSK9 antibody is to be administered to a patient at a dose of about 105 mg to about 280 mg subcutaneously once every two weeks, and wherein the serum LDL cholesterol level of the patient is lowered at least about 30 -50% for about 7-14 days.

56. The use of claim 52, wherein the anti-PCSK9 antibody is to be administered to a patient at a dose of about 280 to about 450 mg subcutaneously once every month, and wherein the serum LDL cholesterol level of the patient is lowered at least about 30 -50% for about 21 to 31 days.

57. The use of claim 55, wherein the anti-PCSK9 antibody is to be administered to a patient at a dose of about 120 mg.

58. The use of claim 55, wherein the anti-PCSK9 antibody is to be administered to a patient at a dose of about 140 mg.

59. The use of claim 56, wherein the anti-PCSK9 antibody is to be administered to a patient at a dose of about 420 mg.

60. The use of claim 50, wherein the at least one anti-PCSK9 antibody is selected from the group consisting of 8A3, 11F1 and 8A1.

61. The use of claim 50, wherein the at least one anti-PCSK9 antibody comprises : a light chain variable region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO:465 and a heavy chain variable region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO:463.

62. The use of any of claim 50, wherein the at least one anti-PCSK9 antibody comprises: a light chain variable region that comprises the amino acid sequence of SEQ ID NO:465 and a heavy chain variable region that comprises the amino acid sequence of SEQ ID NO:463.

63. The use of claim 50, wherein the at least one anti-PCSK9 antibody is 11F1.

64. The use of claim 61, wherein the anti-PCSK9 antibody is to be administered to a patient at a dose of about 150 mg subcutaneously once every other week wherein the serum LDL cholesterol level of the patient is lowered at least about 30-50% for about 7-14 days.

65. The use of claim 62, wherein the anti-PCSK9 antibody is to be administered to a patient at a dose of about 150 mg subcutaneously once every four weeks wherein the serum LDL cholesterol level of the patient is lowered at least about 30-50% for about 21-31 days.

66. The use of claim 62, wherein the anti-PCSK9 antibody is to be administered to a patient at a dose of about greater than 150 mg to about 200 mg subcutaneously once every four weeks wherein the serum LDL cholesterol level of the patient is lowered at least about 30-50% for about 21-31 days.

67. The use of claim 52, wherein the at least one anti-PCSK9 antibody is to be administered to the patient before, after or with at least one other cholesterol-lowering agent.

68. The use of claim 67, wherein the at least one other cholesterol lowering agent is selected from the group consisting of: statins, including, atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, Nicotinic acid, Fibric acid, Bile acid sequestrants, Cholesterol absorption inhibitor, lipid modifying agents, PPAR gamma agonists, PPAR alpha/gamma agonists, squalene synthase inhibitors, CETP inhibitors, anti-hypertensives, anti-diabetic agents, including sulphonyl ureas, insulin, GLP-1 analogs, DDPIV inhibitors, ApoB modulators, MTP inhibitoris and /or arteriosclerosis obliterans treatments, oncostatin M, estrogen, berbine and a therapeutic agent for an immune-related disorder.

69. The use of claim 62, wherein the at least one anti-PCSK9 antibody is to be administered to the patient before, after or with at least one other cholesterol-lowering agent.

70. The use of claim 69, wherein the at least one other cholesterol lowering agent is selected from the group consisting of: statins, including, atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, Nicotinic acid, Fibric acid, Bile acid sequestrants, Cholesterol absorption inhibitor, lipid modifying agents, PPAR gamma agonists, PPAR alpha/gamma agonists, squalene synthase inhibitors, CETP inhibitors, anti-hypertensives, anti-diabetic agents, including sulphonyl ureas, insulin, GLP-1 analogs, DDPIV inhibitors, ApoB modulators, MTP inhibitoris and /or arteriosclerosis obliterans treatments, oncostatin M, estrogen, berbine and a therapeutic agent for an immune-related disorder.